Evidence map›Paper›PMID 33851185›Full record

ArticlemedRxiv : the preprint server for health sciences2021

Neutralization of SARS-CoV-2 variants by convalescent and vaccinated serum.

Timothy A Bates, Hans C Leier, Zoe L Lyski, Savannah K McBride, Felicity J Coulter, Jules B Weinstein, James R Goodman, Zhengchun Lu, Sarah A R Siegel, Peter Sullivan and 6 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Timothy A Bates *Department of Molecular Microbiology & Immunology, Oregon Health & Science University (OHSU), Portland, OR 97239, USA.
Hans C Leier *Department of Molecular Microbiology & Immunology, Oregon Health & Science University (OHSU), Portland, OR 97239, USA.
Zoe L LyskiDepartment of Molecular Microbiology & Immunology, Oregon Health & Science University (OHSU), Portland, OR 97239, USA.
Savannah K McBrideDepartment of Molecular Microbiology & Immunology, Oregon Health & Science University (OHSU), Portland, OR 97239, USA.
Felicity J CoulterDepartment of Molecular Microbiology & Immunology, Oregon Health & Science University (OHSU), Portland, OR 97239, USA.
Jules B WeinsteinDepartment of Molecular Microbiology & Immunology, Oregon Health & Science University (OHSU), Portland, OR 97239, USA.
James R GoodmanMedical Scientist Training Program, Oregon Health & Science University (OHSU), Portland, OR 97239, USA.
Zhengchun LuDepartment of Molecular Microbiology & Immunology, Oregon Health & Science University (OHSU), Portland, OR 97239, USA.
Sarah A R SiegelOHSU-PSU School of Public Health, Program in Epidemiology, Portland, OR 97339.
Peter SullivanOHSU-PSU School of Public Health, Program in Epidemiology, Portland, OR 97339.
Matt StrnadOHSU-PSU School of Public Health, Program in Epidemiology, Portland, OR 97339.
Amanda E BruntonOHSU-PSU School of Public Health, Program in Epidemiology, Portland, OR 97339.
David X LeeDepartment of Molecular Microbiology & Immunology, Oregon Health & Science University (OHSU), Portland, OR 97239, USA.
Marcel E CurlinUSA Department of Medicine, Division of Infectious Diseases, Oregon Health & Science University (OHSU), Portland, OR 97239, USA.
William B MesserDepartment of Molecular Microbiology & Immunology, Oregon Health & Science University (OHSU), Portland, OR 97239, USA.
Fikadu G TafesseDepartment of Molecular Microbiology & Immunology, Oregon Health & Science University (OHSU), Portland, OR 97239, USA.

Funding

INTERACTIONS AT THE MICROBE/HOST INTERFACET32AI007472 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI LANDFEAR, SCOTT M · 1995 to 2019
$6.7M
Long Term Immunity Following Yellow Fever VaccinationR01AI145835 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI MESSER, WILLIAM · 2020 to 2024
$3.2M
NIAID NIH HHS R01 AI145835NIAID NIH HHS T32 AI007472
6 · The paper itself

Abstract

We tested human sera from large, demographically balanced cohorts of BNT162b2 vaccine recipients (n=51) and COVID-19 patients (n=44) for neutralizing antibodies against SARS-CoV-2 variants B.1.1.7 and B.1.351. Although the effect is more pronounced in the vaccine cohort, both B.1.1.7 and B.1.351 show significantly reduced levels of neutralization by vaccinated and convalescent sera. Age is negatively correlated with neutralization in vaccinee, and levels of variant-specific RBD antibodies are proportional to neutralizing activities.

Identifiers

PMID33851185
PMCPMC8043482

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.